GPRC5D Therapy: Unique Challenges in Adverse Event Management

Opinion
Video

Lisa Hwa, APRN, DNP, CNP, FAPO, describes the unique challenges in managing adverse events associated with GPRC5D therapy compared with other bispecifics.

Recent Videos
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
Related Content